| Code | CSB-RA723415MB2HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to Ansipastobart, targeting NT5E (ecto-5'-nucleotidase), also known as CD73. NT5E is a cell surface enzyme that catalyzes the conversion of extracellular adenosine monophosphate to adenosine, playing a critical role in purinergic signaling and immune regulation. By generating adenosine in the tumor microenvironment, NT5E contributes to immunosuppression by inhibiting T cell and NK cell function while promoting regulatory T cell activity. Elevated NT5E expression has been associated with various malignancies, including triple-negative breast cancer, ovarian cancer, and melanoma, where it correlates with poor prognosis and immune evasion.
Ansipastobart is a clinical-stage therapeutic antibody designed to block NT5E enzymatic activity, thereby reducing adenosine-mediated immunosuppression and potentially enhancing anti-tumor immune responses. This biosimilar antibody provides researchers with a valuable tool for investigating NT5E-mediated immune regulation, studying adenosine pathway mechanisms in cancer biology, and exploring combination immunotherapy strategies in preclinical models.
There are currently no reviews for this product.